disease genetic disorder results destruction nerve cells brain spinal common form infantile disease becomes apparent around age three six months age baby losing ability turn sit followed seizures hearing loss inability move death usually occurring age three less commonly disease may occur later childhood adolescence adulthood juvenile forms tend less juvenile form typically results death age disease caused genetic mutation hexa gene chromosome codes subunit hexosaminidase enzyme known hexosaminidase inherited autosomal recessive mutation disrupts activity enzyme results buildup molecule ganglioside within cells leading diagnosis may supported measuring blood hexosaminidase level genetic disease type gangliosidosis treatment disease supportive may involve multiple specialities well psychosocial support disease rare general ashkenazi jews french canadians southeastern quebec old order amish pennsylvania cajuns southern louisiana condition approximately ashkenazi jews birth disease named british ophthalmologist waren tay first described symptomatic red spot retina eye american neurologist bernard sachs described cellular changes noted increased rate disease ashkenazi carriers single allele typically hypothesized carrier may confer protection tuberculosis explaining persistence allele certain researchers looking gene therapy enzyme replacement therapy possible disease typically first noticed infants around months old displaying abnormally strong response sudden noises stimuli known startle response may also listlessness muscle stiffness hypertonia disease classified several forms differentiated based onset age neurological infants disease appear develop normally first six months birth neurons become distended gangliosides relentless deterioration mental physical abilities begins child may become blind deaf unable swallow atrophied paralytic death usually occurs age juvenile disease rarer forms usually initially seen children two ten years old people disease experience cognitive motor skill deterioration dysarthria dysphagia ataxia death usually occurs ages five fifteen rare form disease known adultonset lateonset disease usually first symptoms contrast forms lateonset disease usually fatal effects stop progressing frequently misdiagnosed characterized unsteadiness gait progressive neurological deterioration symptoms lateonset typically begin seen adolescence early adulthood include speech swallowing difficulties unsteadiness gait spasticity cognitive decline psychiatric illness particularly schizophrenialike lateonset patients may become fully diseases molecular genetics became known juvenile adult forms disease always recognized variants disease postinfantile often misdiagnosed another neurological disorder friedreichs disease autosomal recessive genetic disorder meaning parents carriers risk giving birth affected child pregnancy affected child would received mutated copy gene child received normal copy one parent mutated copy carriermedical citation needed results mutations hexa gene chromosome encodes alphasubunit betanacetylhexosaminidase lysosomal enzyme different mutations identified human hexa mutations included single base insertions deletions splice phase mutations missense mutations complex patterns mutations alters genes protein product ie enzyme sometimes severely inhibiting recent years population studies pedigree analysis shown mutations arise spread within small founder initial research focused several founder populations early biochemical basis disease first becoming known mutations sequenced directly genetic diseases researchers era yet know common polymorphisms would prove jewish fur trader hypothesis implication single mutation must spread one population another reflected knowledge subsequent research however proven large variety different hexa mutations cause disease one first genetic disorders widespread genetic screening possible one first genetic disorders prevalence compound heterozygosity compound heterozygosity ultimately explains diseases variability including lateonset forms disease potentially result inheritance two unrelated mutations hexa gene one parent classic infantile disease results child inherited mutations parents completely stop biodegradation gangliosides late onset forms occur due diverse mutation base people disease may technically heterozygotes two differing hexa mutations inactivate alter inhibit enzyme activity patient least one hexa copy still enables level hexosaminidase activity later onset disease form occurs disease occurs two unrelated mutations patient said compound heterozygous carriers individuals inherit one mutant allele show abnormal enzyme activity manifest disease symptoms phenomenon called dominance biochemical reason wildtype alleles dominance nonfunctional mutant alleles inborn errors metabolism comes enzymes function enzymes protein catalysts chemical reactions catalysts speed reactions without used process small enzyme quantities required carry reaction someone homozygous nonfunctional mutation enzymeencoding gene little enzyme activity manifest abnormal phenotype ie develop fullblown disease normalmutated heterozygote heterozygous individual also known carrier least half normal enzyme activity level due expression wildtype allele level normally enough enable normal functioning thus prevent phenotypic expression ie normalmutated carrier become disease caused insufficient activity enzyme hexosaminidase hexosaminidase vital hydrolytic enzyme found lysosomes breaks sphingolipids hexosaminidase longer functioning properly lipids accumulate brain interfere normal biological processes hexosaminidase specifically breaks fatty acid derivatives called gangliosides made biodegraded rapidly early life brain develops patients carriers identified simple blood test measures hexosaminidase hydrolysis requires three proteins two subunits hexosaminidase third small glycolipid transport protein activator protein acts substratespecific cofactor enzyme deficiency one proteins leads ganglioside storage primarily lysosomes neurons disease along abvariant sandhoff disease occurs mutation inherited parents deactivates inhibits process mutations probably directly affect protein functional elements eg active site instead cause incorrect folding disrupting function disable intracellular patients clinical suspicion disease age onset initial testing involves enzyme assay measure activity hexosaminidase serum fibroblasts leukocytes total hexosaminidase enzyme activity decreased individuals percentage hexosaminidase confirmation decreased enzyme activity individual confirmation molecular analysis patients infantile onset disease cherry red macula retina easily observable physician using red spot retinal area appears red gangliosides surrounding retinal ganglion cells choroidal circulation showing red foveal region retinal ganglion cells pushed aside increase visual acuity thus cherryred spot normal part retina shows contrast rest retina microscopic analysis retinal neurons shows distended excess ganglioside unlike lysosomal storage diseases eg gaucher disease disease sandhoff disease hepatosplenomegaly liver spleen enlargement seen three main approaches used prevent reduce incidence treatment addressed cause disease could slow progression people receive supportive care ease symptoms extend life reducing chance contracting infants given feeding tubes longer lateonset medication eg lithium depression sometimes control psychiatric symptoms seizures although medications eg tricyclic antidepressants phenothiazines haloperidol risperidone associated significant adverse even best care children infantile disease usually die age children juvenile form likely die ages lifespans adult form probably ashkenazi jews high incidence lipid storage diseases united states ashkenazi jews recessive carrier disease incidence every newborn among ashkenazi french canadians cajun community louisiana occurrence similar ashkenazi jews irish americans chance general population incidence carriers heterozygotes incidence approximately newborns general population united three general classes theories proposed explain high frequency carriers ashkenazi jewish population disease one first genetic disorders epidemiology studied using molecular data studies mutations using new molecular techniques linkage disequilibrium coalescence analysis brought emerging consensus among researchers supporting founder effect waren tay bernard sachs two physicians described diseases progression provided differential diagnostic criteria distinguish neurological disorders similar tay sachs reported first cases among ashkenazi jewish families tay reported observations first volume proceedings british ophthalmological society founding seen three cases single family years later bernard sachs american neurologist reported similar findings reported case arrested cerebral development new york neurological society sachs recognized disease familial basis proposed disease called amaurotic familial idiocy however genetic basis still poorly understood although gregor mendel published article genetics peas mendels paper largely forgotten generation rediscovered scientists thus mendelian model explaining unavailable scientists doctors time first edition jewish encyclopedia published volumes described known curious fact amaurotic family idiocy rare fatal disease children occurs mostly among jews largest number cases observed united thirty number first thought exclusively jewish disease cases first reported russian polish jews recently reported cases occurring nonjewish children chief characteristics disease progressive mental physical enfeeblement weakness paralysis extremities marasmus associated symmetrical changes macula lutea investigation reported cases found neither consanguinity syphilitic alcoholic nervous antecedents family history factors etiology disease preventive measures yet discovered treatment benefit cases terminated fatally jewish immigration united states peaked period immigrants arriving russia countries eastern europe also period nativism hostility immigrants united states opponents immigration often questioned whether immigrants southern eastern europe could assimilated american society reports disease contributed perception among nativists jews inferior shintaro okada john obrien showed disease caused enzyme defect also proved patients could diagnosed assay hexosaminidase development enzyme assays demonstrated levels hexosaminidases b could measured patients carriers allowing reliable detection heterozygotes early researchers developed protocols newborn testing carrier screening prenatal end researchers identified three variant forms gangliosidosis including sandhoff disease ab variant accounting false negatives carrier since carrier testing began millions ashkenazi jews screened carriers jewish communities embraced cause genetic screening success disease led israel become first country offers free genetic screening counseling couples opened discussions proper scope genetic testing disorders disease one first autosomal recessive genetic disorders enzyme assay test prior polymerase chain reaction testing methods intensely studied model diseases researchers sought evidence selective process continuing controversy whether heterozygotes carriers selective advantage presence four different lysosomal storage disorders ashkenazi jewish population suggests past selective advantage heterozygous carriers controversy among researchers reflected various debates among geneticists enzyme replacement therapy techniques investigated lysosomal storage disorders could potentially used treat well goal would replace nonfunctional enzyme process similar insulin injections diabetes however previous studies hexa enzyme thought large pass specialized cell layer blood vessels forms barrier humanscitation needed researchers also tried directly instilling deficient enzyme hexosaminidase cerebrospinal fluid csf bathes brain however intracerebral neurons seem unable take physically large molecule efficiently even directly therefore approach treatment disease also ineffective disease exists jacob biochemical mechanism disease jacob sheep virtually identical humans wherein diminished activity hexosaminidase results increased concentrations ganglioside affected sequencing hexa gene cdna affected jacobs sheep reveal identical number nucleotides exons human hexa gene nucleotide sequence missense mutation found hexa cdna affected sheep mutation single nucleotide change end exon resulting exons deletion translation via splicing model provided jacob sheep first offer promise means gene therapy clinical trials may prove useful disease treatment experimental methods researched involve substrate reduction therapy attempts use alternative enzymes increase brains catabolism gangliosides point residual degradative activity sufficient prevent substrate one experiment demonstrated using enzyme sialidase allows genetic defect effectively bypassed consequence gangliosides metabolized levels become almost inconsequential safe pharmacological treatment developed one increases expression lysosomal sialidase neurons without toxicity new form therapy could essentially cure another metabolic therapy investigation disease uses drug reversible inhibitor enzyme glucosylceramide synthase catalyzes first step synthesizing glucosebased glycosphingolipids like disease deficiency βhexosaminidase deterioration affected individuals could slowed stopped use substance increases activity however since infantile disease βhexosaminidase treatment would ineffective people affected lateonset disease βhexosaminidase present treatment may effective drug pyrimethamine shown increase activity βhexosaminidase however increased levels βhexosaminidase still fall far short desired normal hexa phenotypic symptoms begin highly invasive procedure involves destroying patients blood system chemotherapy administering cord blood five people received treatment two still alive five years still great deal health critics point procedures harsh fact unapproved significant issues involve difficulty crossing barrier well great expense unit cord blood costs adult recipients need many february first ever gene therapy announced uses adenoassociated virus aav deliver correct instruction hexa gene brain cells causes disease two children part compassionate trial presenting improvements natural course disease vectorrelated adverse